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Summary 
 
In the last two decades, evidence for a link between the gut microbiome 
with the host metabolism and metabolic disorders like insulin resistance and type 
2 diabetes mellitus has constantly increased. The gut microbiota can ferment 
indigestible carbohydrates (saccharolytic fermentation) and produce the major 
short chain fatty acids (SCFA) acetate, propionate and butyrate mainly in the 
proximal colon. Of relevance, SCFA have been linked to improvements in 
substrate handling at the tissue level contributing to an amelioration in insulin 
sensitivity and metabolic health. Additionally, fermentation of peptides and 
proteins (proteolytic fermentation), mainly occurring in the distal colon, yields 
products such as branched chain fatty acids (BCFA), which may have adverse 
effects on gut and metabolic health. However, most literature is based on animal 
studies and only a limited amount of human studies are available. Hence, in this 
thesis we focused on the role of gut-derived metabolites (SCFA and BCFA) in in 
vivo metabolic health in human cross-sectional and intervention studies with 
overweight and obese individuals as well as the role of SCFA in human adipose 
tissue and skeletal muscle derived in vitro models. 
In chapter 2, we extensively reviewed findings on the most abundant SCFA 
acetate in the context of body weight control and insulin sensitivity. We discuss 
that circulating acetate may have tissue-specific metabolic effects (liver, skeletal 
muscle, adipose tissue and pancreatic beta cells) and potentially impact whole-
body energy and substrate metabolism (satiety, energy expenditure, fat oxidation) 
resulting in an improved metabolic health and insulin sensitivity. In addition, we 
discuss that the effectiveness of interventions (pre- probiotics, synbiotics) aiming 
to increase acetate concentrations in the colon as well as in the circulation may 
depend on colonic production site. In this respect, differences in the site of acetate 
production (proximal vs distal colon) as well as the differences in colonic acetate 
release into the circulation have to be taken into account. Furthermore, we discuss 
that future interventions (using prebiotics, probiotics, synbiotics and/or vinegar 
administrations) with the aim to increase circulating acetate should be more 
personalized and thereby consider both metabolic and microbial phenotype of 
participants. 
Interestingly, it has been shown that the relationship between gut 
microbiota and insulin sensitivity may be sex-specific in humans. Therefore, in 
chapter 3, we investigated whether the associations between circulating acetate 
with insulin sensitivity/resistance indices (Homeostatic Model Assessment of 
Insulin Resistance (HOMA-IR), circulating insulin and Matsuda index) were 
different in male and female participants (BMI >27 kg/m2, n=478) of the Diet, 
Obesity and Genes (DiOGenes) study before and after a low-calorie diet (LCD, 800 
kcal/d). We found that acetate was positively associated with insulin resistance in 
females, but not in males, even after adjustment for age, BMI and fat free mass.  
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Of note, these findings warrant further investigations to understand the 
sex-specific differences in circulating acetate and their potential role in metabolic 
health during weight loss. In particular, factors contributing to circulating fasting 
acetate such as hormonal status, endogenous liver production (ketogenesis) 
and/or the gut-derived production of acetate should be considered. Furthermore, 
future studies should investigate acetate dynamics to fully elucidate the role of 
circulating acetate in metabolic health. 
So far, in human studies gut microbial-derived SCFA have been mainly 
measured in feces. However, fecal SCFA production should be interpreted with 
caution, since they are the net result of colonic production, absorption rates and 
release into the circulation, which are intricately influenced by microbial 
composition, cross-feeding mechanisms and whole gut transit time among other 
factors. Therefore, in chapter 4, we investigated associations between fecal and 
plasma SCFA (acetate, propionate and butyrate) with metabolic health markers 
including circulating metabolites, gut hormones, substrate oxidation, 
inflammatory parameters and markers of insulin sensitivity in a well-phenotyped 
group of individuals with a large range in BMI and glucometabolic status. 
Interestingly, we found that plasma, not fecal, SCFA (acetate, propionate and 
butyrate) associated negatively with circulating markers of lipid metabolism and 
positively with circulating GLP-1 levels. The negative associations with circulating 
lipids (glycerol, triglycerides, free fatty acids, respectively) are in line with 
previous literature, suggesting a relationship between SCFA and adipose tissue 
metabolism and possible improvements in adipose tissue lipid buffering capacity. 
An interesting (novel) finding was the positive association of circulating SCFA 
with fasting GLP-1 levels possibly indicating a link of plasma SCFA with gut-
hormone secretion. In a subgroup analysis, we found that insulin sensitivity (as 
measured by the golden standard hyperinsulinaemic-euglycemic clamp 
technique) associated with circulating SCFA but that the direction of this 
association depended on type of SCFA (acetate negatively and propionate 
positively). Although controversial associations of circulating acetate and insulin 
sensitivity have been found (in chapter 3 and chapter 4), findings should be 
interpreted with caution taking into consideration that circulating acetate is 
affected by various factors including liver endogenous production (ketogenesis), 
gut-derived production as well as metabolic and microbial phenotype. 
Besides saccharolytic fermentation and SCFA production, proteolytic 
fermentation may yield various metabolites such as BCFA (i.e. isobutyrate, 
isovalerate), which role in human substrate and energy metabolism remains 
largely unclear. In addition, research on other fecal metabolites derived from 
saccharolytic fermentation (i.e. valerate, lactate) is largely lacking. Therefore, in 
chapter 5, we investigated fecal BCFA (isobutyrate and isovalerate) and other fecal 
microbial metabolites (valerate, lactate, succinate and caproate) in insulin sensitive 
and insulin resistant individuals. Additionally, we assessed the relationship of 
fecal microbial metabolites with circulating metabolites, substrate oxidation, and 
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markers of insulin sensitivity (circulating insulin and HOMA-IR). Here, we found 
no significant differences in fecal BCFA concentrations between insulin sensitive 
and insulin resistant individuals. Additionally, there were no associations 
between BCFA and markers of insulin resistance and metabolic health. Further 
human studies are warranted to investigate the role of these microbially-derived 
fermentation products and their kinetics in metabolic health and insulin 
sensitivity.  
In chapter 6, we investigated whether our previously observed increments 
in in vivo fat oxidation after colonic acetate administration in humans were 
mediated through direct effects of circulating acetate on the skeletal muscle fat 
oxidation. Therefore, we investigated the effects of sodium acetate on fat oxidation 
in human primary muscle cells (HSkMC) derived from a healthy insulin sensitive 
donor. We observed no direct sodium acetate-mediated effects neither on 
endogenous nor on exogenous fat oxidation in our human skeletal muscle cell 
model using physiologically relevant sodium acetate concentrations. 
Additionally, we observed no dose and time effect of sodium acetate on total and 
phosphorylated AMPK levels. However, we cannot exclude that our previously 
observed in vivo human effects on fat oxidation after colonic acetate 
administrations occur in tissues other than skeletal muscle (i.e. liver fat oxidation) 
or are mediated by other gut-derived metabolites or hormones (i.e. PYY). 
Additionally, the lack of effect on in vitro muscle fat oxidation may be donor-
dependent, muscle fiber type-specific as well as species-specific and warrants 
further investigation.  
In several animal as well as human in vivo studies an anti-lipolytic effect of 
SCFA was demonstrated, which may reduce systemic lipid overflow and 
ultimately result in improvements in insulin sensitivity. Therefore, in chapter 7, 
we used the human multipotent adipose-derived stem (hMADS) cell model to 
study the effects of SCFA on (cytosolic) lipolysis and to elucidate the potential 
underlying mechanisms. We found that SCFA differentially affect adipose tissue 
lipolysis, and in particular that acetate is the major SCFA responsible for the 
decreased basal and β-adrenergically stimulated glycerol release in our in vitro 
hMADS cell model. The latter anti-lipolytic effect was mediated through a GPR-
dependent reduction in phosphorylation of hormone sensitive lipase (HSL). Thus, 
these data suggest that circulating acetate affect adipose tissue lipolysis, thereby 
possibly limiting lipid overflow and improving insulin sensitivity.  
In conclusion, this doctoral thesis provides an increased insight in the role 
of saccharolytic (major SCFA as well as other less studied metabolites) and 
proteolytic fermentation products (BCFA) in insulin sensitivity and substrate 
metabolism in human cohorts as well as in in vitro studies. The main findings 
indicate that gut-derived metabolites (SCFA) in the circulation might be a better 
indicator of their effects on metabolic health as compared to fecal concentrations.  
Furthermore, the present data suggest that the sex-specific relationship of 
circulating acetate with insulin sensitivity exist, which may depend on various 
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factors such as endogenous liver metabolism, hormonal profile, and microbial and 
metabolic phenotype. 
 Lastly, our in vitro experiments provided valuable mechanistic insight on 
the relation between acetate and skeletal muscle fat oxidation and adipose tissue 
lipolysis, which needs to be investigated in more detail in human in vitro and in 
vivo studies. Additionally, future studies need to consider SCFA and BCFA 
dynamics (production, absorption and release into the circulation), colonic 
production site as well as the role of these gut-derived metabolites in tissue and 
whole-body metabolism and metabolic health. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
